Methylfolate as Monotherapy in Depression. A Pilot Randomised Controlled Trial

Journal Title: Journal of Neurology and Psychology - Year 2015, Vol 3, Issue 1

Abstract

Background: The commonest neuropsychiatric complication of severe folate deficiency is depression. Placebo controlled trials of folates as adjunctive therapy in major depression have confirmed that they enhance the response to standard antidepressant medication, even in the absence of folate deficiency. We have undertaken a pilot randomised controlled trial of 5-methyltetrahydrofolate (5- MTHF) monotherapy against Amitriptyline in out-patients with mild to moderate depression. Methods: 31 patients, aged 20 – 69 years with DSM-111-R criteria for a depressive episode of mild to moderate severity and a Montgomery Asberg Depression Score (MADS) of at least 14 were randomly allocated to 5-MTHF 50 mgs (25 mgs biologically active) or Amitriptyline 150 mgs for 6 weeks. Clinical response was defined as a fall in MADS of 25% or more. Non-responders to initial therapy were crossed over to the alternative active therapy for a further six weeks. Haemoglobin, mean cell volume, serum and red cell folate and serum vitamin B12 were measured at entry to the study, after six weeks of initial and crossover treatment and at six months. Results: Of 19 patients randomised (n = 16) or crossed over (n = 3) to treatment with 5-MTHF for six weeks, eight (42%) responded. Of 20 patients randomised (n = 15) or crossed over (n = 5) to Amitriptyline, seven (35%) responded. Only 3 patients (10%) had low or borderline red cell folate values at randomisation. Response to 5-MTHF was associated with a significantly greater rise in red cell folate. Conclusions: Placebo controlled trials of 5-MTHF as monotherapy in depression would be justifiable. Our observations together with studies of S-adenosylmethionine (SAM) and nitrous oxide (N2O) are consistent with the hypothesis that 5-MTHF has intrinsic mood elevating properties in some patients.

Authors and Affiliations

Edward H Reynolds

Keywords

Related Articles

The Relationship between Stress and Diabetes Mellitus

Diabetes mellitus (DM) is a metabolic disease characterized by chronic hyperglycemia that results from an alteration of the secretion or action of insulin. This metabolic condition is not homogeneous and the World Health...

Methylfolate as Monotherapy in Depression. A Pilot Randomised Controlled Trial

Background: The commonest neuropsychiatric complication of severe folate deficiency is depression. Placebo controlled trials of folates as adjunctive therapy in major depression have confirmed that they enhance the respo...

Koro-Like Syndrome in an Iranian 50 Years Old Man; Is It A Variant Caused by Cultural Issues?

Koro syndrome is a psychiatric disorder characterized by acute anxiety of one’s genital retraction. In this culture-bound syndrome, originally reported in south and East Asia, the male individual believes that his penis...

Interpersonal Psychotherapy Efficacy in Different Clinical Settings

Interpersonal therapy is an effective brief and limited therapy originally developed for major depression disorder but nowadays also highly effective in other psychiatric disorders [1,2]. This therapy uses the biopsychos...

Neuronal Endosomal Trafficking: One of the Common Molecular Pathways Disrupted in Autism Spectrum Disorders and Schizophrenia

Current research has examined the overlap of genetic risk factors and phenotypic behaviors in Autism Spectrum Disorders (ASDs) and Schizophrenia (SZ). We compiled a table of functional groups of genes altered in both ASD...

Download PDF file
  • EP ID EP197342
  • DOI 10.13188/2332-3469.1000019
  • Views 142
  • Downloads 0

How To Cite

Edward H Reynolds (2015). Methylfolate as Monotherapy in Depression. A Pilot Randomised Controlled Trial. Journal of Neurology and Psychology, 3(1), 1-5. https://europub.co.uk/articles/-A-197342